secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001213900-24-097145
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Q3 net loss $4.1M; OLC NDA accepted with PDUFA June 2025
------------------------------------------------------------------

- Net loss $4.1M vs $4.4M YoY; cash $32.3M expected to fund into 2026.
- FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.
- OLC patient survey: 79% preferred OLC over prior therapy; 98% said easy to take.
- UNI-494 Phase 1 completed; plans to request FDA meeting by end of 2024.
- Added to Russell Microcap Index effective July 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024097145/0001213900-24-097145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024097145/ea0220889-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-097145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer